A Drug-drug Interaction Study Between the Novel Anti-HCV Agent Daclatasvir and the Antiretroviral Agents Atazanavir/Ritonavir or Atazanavir/Cobicistat in Healthy Volunteers

Trial Profile

A Drug-drug Interaction Study Between the Novel Anti-HCV Agent Daclatasvir and the Antiretroviral Agents Atazanavir/Ritonavir or Atazanavir/Cobicistat in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Daclatasvir (Primary) ; Atazanavir; Cobicistat; Ritonavir
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Acronyms DATE-4
  • Most Recent Events

    • 20 Oct 2016 Results published in the Journal of Antimicrobial Chemotherapy
    • 25 Jan 2016 Status changed from not yet recruiting to completed, as reported by ClinicalTrials.gov.
    • 08 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top